207 related articles for article (PubMed ID: 33008805)
21. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
22. ZIP restores estrogen receptor expression and response to Tamoxifen in estrogen receptor negative tumors.
Zhu N; Zhang J; Qin X; Miao R; Du Y; Yang J
Biochem Biophys Res Commun; 2016 Nov; 480(4):570-573. PubMed ID: 27793668
[TBL] [Abstract][Full Text] [Related]
23. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
Plaza-Menacho I; Morandi A; Robertson D; Pancholi S; Drury S; Dowsett M; Martin LA; Isacke CM
Oncogene; 2010 Aug; 29(33):4648-57. PubMed ID: 20531297
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
25. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.
Pontiggia O; Sampayo R; Raffo D; Motter A; Xu R; Bissell MJ; Joffé EB; Simian M
Breast Cancer Res Treat; 2012 Jun; 133(2):459-71. PubMed ID: 21935603
[TBL] [Abstract][Full Text] [Related]
26. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
27. The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8.
Shi JJ; Chen SM; Guo CL; Li YX; Ding J; Meng LH
Acta Pharmacol Sin; 2018 Aug; 39(8):1338-1346. PubMed ID: 29345254
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance.
Louie MC; McClellan A; Siewit C; Kawabata L
Mol Cancer Res; 2010 Mar; 8(3):343-52. PubMed ID: 20215421
[TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
[TBL] [Abstract][Full Text] [Related]
30. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity.
Shekhar MP; Santner S; Carolin KA; Tait L
Am J Pathol; 2007 May; 170(5):1546-60. PubMed ID: 17456761
[TBL] [Abstract][Full Text] [Related]
31. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
32. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
33. Autophagy and endocrine resistance in breast cancer.
Cook KL; Shajahan AN; Clarke R
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1283-94. PubMed ID: 21916582
[TBL] [Abstract][Full Text] [Related]
34. CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK/mTOR pathway.
Wu ST; Sun GH; Cha TL; Kao CC; Chang SY; Kuo SC; Way TD
J Biomed Sci; 2016 Aug; 23(1):60. PubMed ID: 27526942
[TBL] [Abstract][Full Text] [Related]
35. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.
Stender JD; Nwachukwu JC; Kastrati I; Kim Y; Strid T; Yakir M; Srinivasan S; Nowak J; Izard T; Rangarajan ES; Carlson KE; Katzenellenbogen JA; Yao XQ; Grant BJ; Leong HS; Lin CY; Frasor J; Nettles KW; Glass CK
Mol Cell; 2017 Mar; 65(6):1122-1135.e5. PubMed ID: 28306507
[TBL] [Abstract][Full Text] [Related]
36. Hormonal Regulation of Semaphorin 7a in ER
Crump LS; Wyatt GL; Rutherford TR; Richer JK; Porter WW; Lyons TR
Cancer Res; 2021 Jan; 81(1):187-198. PubMed ID: 33122307
[TBL] [Abstract][Full Text] [Related]
37. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
38. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
39. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells.
Duan L; Calhoun S; Shim D; Perez RE; Blatter LA; Maki CG
J Mol Cell Biol; 2021 Sep; 13(6):433-444. PubMed ID: 33755174
[TBL] [Abstract][Full Text] [Related]
40. Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer.
Tsuboi K; Uematsu C; Yamaguchi Y; Niwa T; Hayashi SI
Breast Cancer; 2019 Nov; 26(6):748-757. PubMed ID: 31119683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
